1. C26-Ceramide as highly sensitive biomarker for the diagnosis of Farber Disease

C26-Ceramide as highly sensitive biomarker for the diagnosis of Farber Disease

Claudia Cozma, MD 1 Marius-Ionuț Iurașcu 1 Sabrina Eichler, PhD 1 Marina Hovakimyan, PhD 1 Oliver Brandau, MD 1 Susanne Zielke 2 Tobias Böttcher, PhD 2 Anne Katrin Giese, MD 2 Jan Lukas, PhD 2 Prof. Arndt Rolfs, MD 1, 2
1 CENTOGENE AG 2 University of Rostock
July 21, 2017

Scientific Reports | 7: 6149 | DOI:10.1038/s41598-017-06604-2

Abstract:

Farber disease (FD) is a rare autosomal recessive disease caused by mutations in the acid ceramidase gene (ASAH1). Low ceramidase activity results in the accumulation of fatty substances, mainly ceramides. Hallmark symptoms at clinical level are periarticular nodules, lipogranulomas, swollen and painful joints and a hoarse voice. FD phenotypes are heterogeneous varying from mild to very severe cases, with the patients not surviving past their first year of life. The diagnostic aspects of FD are poorly developed due to the rarity of the disease. In the present study, the screening for ceramides and related molecules was performed in Farber affected patients (n = 10), carriers (n = 11) and control individuals (n = 192). This study has the highest number of enrolled Farber patients and carriers reported to present. Liquid chromatography multiple reaction mass spectrometry (LC/MRM-MS) studies revealed that the ceramide C26:0 and especially its isoform 1 is a highly sensitive and specific biomarker for FD (p < 0.0001). The new biomarker can be determined directly in the dried blood spot extracts with low sample consumption. This allows for easy sample preparation, high reproducibility and use in high throughput screenings.